Target
Fibroblast Growth Factor Receptor (FGFR)
4 abstracts
Abstract
Safety and efficacy of CyberKnife radiosurgery plus anlotinib hydrochloride in patients with recurrent glioblastoma: A prospective phase II single-arm study.Org: CyberKnife Center, Department of Neurosurgery, Prince of Wales Hospital, Huashan Hospital, Shanghai Medical College, Fudan University, Fudan University Shanghai Cancer Center, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).Org: Medical Oncology, Vall d'Hebron Institute of Oncology, Division of Medical Oncology, National Cancer Centre Singapore,
Abstract
Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: A single-center, single-arm, phase II trial.Org: Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China,